MainStreet Investment Advisors LLC lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 193.7% during the 1st quarter, Holdings Channel reports. The firm owned 5,866 shares of the medical research company’s stock after buying an additional 3,869 shares during the quarter. MainStreet Investment Advisors LLC’s holdings in Amgen were worth $1,189,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Salomon & Ludwin LLC grew its holdings in shares of Amgen by 125.0% in the 4th quarter. Salomon & Ludwin LLC now owns 108 shares of the medical research company’s stock worth $26,000 after purchasing an additional 60 shares during the last quarter. Savior LLC bought a new stake in Amgen during the 4th quarter worth about $34,000. CLS Investments LLC grew its holdings in Amgen by 175.4% during the 4th quarter. CLS Investments LLC now owns 157 shares of the medical research company’s stock worth $38,000 after acquiring an additional 100 shares during the last quarter. Sageworth Trust Co bought a new stake in Amgen during the 4th quarter worth about $42,000. Finally, Altshuler Shaham Ltd grew its holdings in Amgen by 273.9% during the 4th quarter. Altshuler Shaham Ltd now owns 172 shares of the medical research company’s stock worth $42,000 after acquiring an additional 126 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:AMGN traded up $1.65 during mid-day trading on Friday, reaching $226.43. The stock had a trading volume of 2,305,494 shares, compared to its average volume of 2,887,619. The firm has a market cap of $132.23 billion, a PE ratio of 17.75, a price-to-earnings-growth ratio of 1.92 and a beta of 0.97. The firm has a 50 day simple moving average of $228.36 and a two-hundred day simple moving average of $225.14. The company has a current ratio of 1.59, a quick ratio of 1.28 and a debt-to-equity ratio of 3.16. Amgen, Inc. has a twelve month low of $166.68 and a twelve month high of $244.99.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share for the quarter, beating analysts’ consensus estimates of $3.70 by $0.47. The business had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $6.01 billion. Amgen had a net margin of 32.03% and a return on equity of 90.75%. Amgen’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period last year, the company posted $3.56 EPS. On average, equities analysts anticipate that Amgen, Inc. will post 15.58 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, June 8th. Investors of record on Monday, May 18th will be given a $1.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.83%. Amgen’s dividend payout ratio is 43.18%.
A number of equities research analysts have commented on AMGN shares. Wolfe Research started coverage on shares of Amgen in a report on Tuesday, March 31st. They set a “market perform” rating and a $218.00 price objective on the stock. Raymond James raised shares of Amgen from a “market perform” rating to an “outperform” rating and set a $255.00 price objective on the stock in a report on Sunday, March 29th. Wells Fargo & Co increased their price objective on shares of Amgen from $220.00 to $237.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Piper Sandler increased their price objective on shares of Amgen from $235.00 to $255.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, Barclays assumed coverage on shares of Amgen in a report on Thursday, February 27th. They set an “equal weight” rating and a $235.00 price objective on the stock. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and seventeen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $244.65.
In other Amgen news, Director Ronald D. Sugar sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $233.35, for a total transaction of $233,350.00. Following the sale, the director now directly owns 15,636 shares in the company, valued at approximately $3,648,660.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $237.31, for a total transaction of $100,856.75. Following the sale, the director now owns 5,834 shares in the company, valued at $1,384,466.54. The disclosure for this sale can be found here. Insiders have sold a total of 2,425 shares of company stock worth $563,477 over the last 90 days. Corporate insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Why do companies engage in swaps?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.